Participated · Series A · Aug 2026

Boldr develops a software and hardware platform—including smart thermostats and connected controls—that gives HVAC contractors visibility and control over installed residential heating and cooling equipment. The company partners with contractors and supply houses (including Bosch-owned Source 1 and Daikin) to deploy and service controls rather than selling directly to homeowners. Its platform is designed to coordinate HVAC systems and eventually batteries, EV chargers and solar to provide flexible capacity to the power grid during periods of high demand. Boldr is initially focused on residential and light commercial HVAC, with plans to expand into central HVAC systems and additional distributed energy assets. The company has raised an oversubscribed $3.2M seed round and a $5M pre-Series A to fund product development and North American distribution expansion.

Participated · Seed · Aug 2026

Medly AI is an exam-prep platform headquartered in London. The company is positioned in the education/edtech space and was described in the report with tags including AI and AITutor. Beyond its classification as an exam-prep platform, the article does not provide product details, user metrics, revenue figures, founding year, or specific growth plans. The only operational detail in the report is its London base and its focus on exam preparation.

Participated · Seed · Jul 2026

Cascade leverages AI to surface engineering, architecture and construction project opportunities by reading signals such as bond filings, permits, budget announcements, capital plans, property transactions, earnings transcripts and meeting minutes. The company says its platform has surfaced more than $10 billion in project opportunities for clients, including firms that build for major projects at JFK and LaGuardia airports. Cascade was founded by Hannia Zia and Joana Ferreira, who previously worked at Google and met at UnlikelyAI. The startup plans to use the seed funding to deepen its network and accelerate customer adoption. The company positions itself as reducing reliance on manual prospecting processes for architecture, engineering and construction firms. No revenue, valuation or prior financing details were disclosed in the article.

Led · Seed · Jul 2026

Tyred builds a connected bike ownership platform that combines IoT sensors, AI-driven predictive maintenance and operational data with bundled services such as servicing, insurance, warranties and finance. The company began in 2022 as a mobile bike repair service and has since expanded into fleet and consumer offerings. Tyred says it has serviced more than 100,000 bicycles over the past year and maintains around 50,000 Lime bikes in London, building a dataset to power its predictive models. Its product aims to flag wear or degrading components before failures occur, reducing reactive repairs for riders and fleet operators. With the new capital the company plans to hire engineering talent, develop its product further and expand across the UK and into European markets. Tyred positions itself as a single dashboard for fragmented ownership services to keep more bikes on the road and simplify ownership.

Led · Seed · Jul 2026

Juno Bio offers an at-home vaginal microbiome test that screens for bacteria, fungi and some sexually transmitted infections, and provides an analysis of microbes linked to conditions like bacterial vaginosis and yeast infections. Tests are available in 46 states and are priced at $149 for a single test or $99 for a test every three months, with patients able to book a free follow-up call with a company coach to review results and next steps. The company cites data indicating 67.5% of its customers had been incorrectly diagnosed before using the test and only 13% had been successfully treated. Juno Bio is establishing a CLIA-certified sequencing lab in Oakland to bring testing in-house, improve turnaround and support future research and clinical standardization. Founder and chief science officer Leighton Turner and CEO Hana Janebdar have framed the next phase as scaling clinical infrastructure, expanding access to actionable care and advancing understanding of the vaginal microbiome.